Chelsea Grow, DO
Neurology · Gulfport, MSNPI 1205997251
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,045 of the $78,382 with a category attached, or 88.1%. AbbVie accounts for 77.3% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $39,399 and has fallen 98.5% since, to $600 in 2025. Among neurology clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $175.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$61K
- Teva Pharmaceuticals USA, Inc.$14K
- Novartis$834
- Amgen$629
- UCB, Inc.$285
- Pfizer$240
- plus $1K from 28 others
What the payments were for
- Consulting fees$1,9002%
- Speaking & faculty fees$69,04588%
- Travel & lodging$1,0711%
- Food & beverage$6,3598%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 194 | $60,626 |
| Teva Pharmaceuticals USA, Inc. | 49 | $14,310 |
| Novartis | 47 | $834 |
| Amgen(2 entities) | 39 | $629 |
| UCB, Inc. | 18 | $285 |
| Pfizer | 15 | $240 |
| Supernus Pharmaceuticals, Inc. | 10 | $222 |
| Acadia Pharmaceuticals Inc | 7 | $125 |
| Octapharma USA, Inc. | 7 | $122 |
| Lundbeck LLC | 7 | $120 |
| Jazz Pharmaceuticals Inc. | 6 | $102 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Harmony Biosciences LLC | 4 | $70 |
| Biohaven Pharmaceuticals, Inc. | 4 | $61 |
| GE HealthCare | 4 | $51 |
| MDD US Operations, LLC | 3 | $48 |
| Mallinckrodt Enterprises LLC | 3 | $47 |
| SK Life Science, Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $40 |
| CSL Behring | 2 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| EMD Serono, Inc. | 2 | $30 |
| Eisai Inc. | 2 | $29 |
| AstraZeneca | 2 | $28 |
| Bristol Myers Squibb | 2 | $27 |
| Biogen | 2 | $26 |
| Argenx US, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Sanofi | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Kls-martin L.p. | 1 | $14 |
| Orthofix Medical, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,382 in reported general payments places this provider in the 90th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $392,457 |
| UbrelvyUbrogepant | 160 | $252,797 |
| Nurtec OdtRimegepant Sulfate | 154 | $180,903 |
| Aimovig AutoinjectorErenumab-Aooe | 114 | $97,789 |
| QuliptaAtogepant | 50 | $70,858 |
| Emgality PenGalcanezumab-Gnlm | 58 | $58,388 |
| BotoxOnabotulinumtoxina | 26 | $42,191 |
| Sumatriptan Succinate | 93 | $9,004 |
| Ajovy SyringeFremanezumab-Vfrm | 12 | $8,427 |
| Ondansetron Hcl | 64 | $6,796 |
| MaxaltRizatriptan Benzoate | 13 | $6,169 |
| Aripiprazole | 21 | $4,847 |
| Sumatriptan Succ-Naproxen SodSumatriptan Succ/Naproxen Sod | 11 | $4,458 |
| Dimethyl Fumarate | 19 | $4,170 |
| Carbamazepine ErCarbamazepine | 37 | $4,138 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Botox | $60,626 | $365,846236 claims |
| PfizerNurtec Odt | $240 | $180,903154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 neurology providers in Mississippi.
Other neurology in Gulfport
- Abha MishraGulfport$12K
- Diane RossGulfport$10K
- Lee VoultersGulfport$9K
- Stephen LandyTupelo$1.9M
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Ronald SchwartzHattiesburg$352K
- Rajesh SharmaJackson$152K
- Paula WarrenHattiesburg$114K
- Justin GraffTupelo$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.